Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 62

Sort by

Sort Order Select

Journal Articles

Enhancing the Antigen-Sensitivity of the CD22 CAR through Modulation of the Affinity and Linker-Length of the Single-Chain Fragment Variable

M. Eric Kohler, MD PhD, Zachary Walsh, Kole Degolier, Terry J. Fry, MD

Blood (2020) 136 (Supplement 1): 41–42.

https://doi.org/10.1182/blood-2020-143372

Published: 2020

Journal Articles

Phase I Trial Using CD19/CD22 Bispecific CAR T Cells in Pediatric and Adult Acute Lymphoblastic Leukemia (ALL)

Blood (2019) 134 (Supplement_1): 744.

https://doi.org/10.1182/blood-2019-129411

Published: 2019

Journal Articles

Infectious Complications Associated with CAR T-Cell Therapy

Lekha Mikkilineni, MD, Shilpa Shahani, MD, Bonnie Yates, NP, Seth M. Steinberg, PhD, Tara Palmore, MD, Veronique Nussenblatt, MD, Daniel W. Lee, MD, Rosandra N. Kaplan, MD, Crystal L. Mackall, MD, Terry J. Fry, MD, Juan Gea-Banacloche, MD, Theresa Jerussi, James N. Kochenderfer, MD, Nirali N. Shah, MD

Blood (2019) 134 (Supplement_1): 4449.

https://doi.org/10.1182/blood-2019-131170

Published: 2019

Journal Articles

Low CD19 Antigen Density Diminishes Efficacy of CD19 CAR T Cells and Can be Overcome By Rational Redesign of CAR Signaling Domains

Robbie G. Majzner, MD, Skyler P. Rietberg, Louai Labanieh, Elena Sotillo, PhD, Evan W. Weber, PhD, Rachel C. Lynn, PhD, Johanna L. Theruvath, MD, Constance M. Yuan, MD PhD, Peng Xu, MD, Sang M. Nguyen, BS, Nirali N. Shah, MD, Maryalice Stetler-Stevenson, MD PhD, Terry J. Fry, MD, Daniel W. Lee, MD, Crystal L. Mackall, MD

Blood (2018) 132 (Supplement 1): 963.

https://doi.org/10.1182/blood-2018-99-115558

Published: 2018

Journal Articles

Phase I Experience with a Bi-Specific CAR Targeting CD19 and CD22 in Adults with B-Cell Malignancies

Nasheed Hossain, MD, Bita Sahaf, PhD, Matthew Abramian, PhD, Jay Y. Spiegel, MD, Katie Kong, Stephen Kim, Sharon Mavroukakis, Jean Oak, MD PhD, Yasodha Natkunam, MD PhD, Everett H Meyer, MD PhD, Matthew J. Frank, MD PhD, Steven A Feldman, PhD, Steven R. Long, MD, Haiying Qin, MS, Terry J. Fry, MD, Lori S Muffly, MD, Crystal L. Mackall, MD, David B. Miklos, MD PhD

Blood (2018) 132 (Supplement 1): 490.

https://doi.org/10.1182/blood-2018-99-110142

Published: 2018

Journal Articles

Phase 1 Study of CD19/CD22 Bispecific Chimeric Antigen Receptor (CAR) Therapy in Children and Young Adults with B Cell Acute Lymphoblastic Leukemia (ALL)

Liora M Schultz, MD, Kara L. Davis, DO, Christina Baggott, RN, PhD, Christie Chaudry, NP, Anne Cunniffe Marcy, MSBH, Sharon Mavroukakis, Bita Sahaf, PhD, Katherine A Kong, Lori S Muffly, MD, Stephen Kim, Everett H Meyer, MD PhD, Terry J. Fry, MD, Haiying Qin, MS, David B. Miklos, MD PhD, Crystal L. Mackall, MD

Blood (2018) 132 (Supplement 1): 898.

https://doi.org/10.1182/blood-2018-99-117445

Published: 2018

Journal Articles

Sequential CD22 Targeting Impacts CD22 CAR-T Cell Response

Bonnie Yates, RN, Haneen Shalabi, DO, Dalia Salem, MD, Cynthia Delbrook, RN, Constance M. Yuan, MD PhD, Maryalice Stetler-Stevenson, MD PhD, Terry J. Fry, MD, Nirali N. Shah, MD

Blood (2018) 132 (Supplement 1): 282.

https://doi.org/10.1182/blood-2018-99-119621

Published: 2018

Journal Articles

CD4/CD8 T-Cell Selection Enhances CD22 CAR-T Cell Transduction and in-Vivo CAR-T Expansion: Updated Results on Phase I Anti-CD22 CAR Dose Expansion Cohort

Nirali N Shah, MD, Steven L Highfill, PhD, Haneen Shalabi, DO, Bonnie Yates, RN, Eli Kane, Vicki Fellowes, Cynthia Delbrook, RN, Jiaqiang Ren, MD PhD, Jianjian Jin, David Stroncek, MD, Terry J. Fry, MD

Blood (2017) 130 (Supplement 1): 809.

https://doi.org/10.1182/blood.V130.Suppl_1.809.809

Published: 2017

Journal Articles

Novel CD19/CD22 Bicistronic Chimeric Antigen Receptors Outperform Single or Bivalent Cars in Eradicating CD19 + CD22 + , CD19 - , and CD22 - Pre-B Leukemia

Haiying Qin, MS, Sang M Nguyen, BS, Sneha Ramakrishna, MD, Samiksha Tarun, MSc, Lila Yang, BS, Nicholas Peter Verdini, BS, Waleed Haso, MS, Terry J. Fry, MD

Blood (2017) 130 (Supplement 1): 810.

https://doi.org/10.1182/blood.V130.Suppl_1.810.810

Published: 2017

Journal Articles

Intensification of Lymphodepletion Optimizes CAR Re-Treatment Efficacy

Haneen Shalabi, DO, Nirali N Shah, MD, Terry J. Fry, MD, Bonnie Yates, RN, Cynthia Delbrook, RN, Constance Yuan, Maryalice Stetler-Stevenson, Sneha Ramakrishna, MD

Blood (2017) 130 (Supplement 1): 3889.

https://doi.org/10.1182/blood.V130.Suppl_1.3889.3889

Published: 2017

Journal Articles

Modulation of CD22 Antigen Density Improves Efficacy of CD22 Chimeric Antigen Receptor (CAR) T Cells Against CD22 lo B-Lineage Leukemia and Lymphoma

Sneha Ramakrishna, MD, Sang M Nguyen, BS, Haiying Qin, MS, Steven L Highfill, PhD, Ira Kraft, John Shern, MD, Zachary Walsh, Dimiter Dimitrov, PhD, Terry J Fry, MD

Blood (2017) 130 (Supplement 1): 3894.

https://doi.org/10.1182/blood.V130.Suppl_1.3894.3894

Published: 2017

Journal Articles

A Direct Comparison of the In Vivo Efficacy and in Vitro Signaling of Chimeric Antigen Receptors and Endogenous T Cell Receptors

Mark Eric Kohler, MD, PhD, Yinmeng Yang, PhD, Gian Sepulveda, Terry J. Fry, MD

Blood (2017) 130 (Supplement 1): 4451.

https://doi.org/10.1182/blood.V130.Suppl_1.4451.4451

Published: 2017

Journal Articles

The Post-Thaw Recovery of Cryopreserved Chimeric Antigen Receptor (CAR) T-Cells during Manufacture Is Better Than That of Cryopreserved Peripheral Blood CD3+ Cells

Nasha Elavia, MD MBBS, Andrew McManus, Steven L Highfill, PhD, Jiaqiang Ren, MD PhD, Nirali N Shah, MD, Terry J. Fry, MD, Jennifer Brudno, MD, James N. Kochenderfer, MD, David Stroncek, MD, Sandhya R. Panch, MDMPH

Blood (2017) 130 (Supplement 1): 4475.

https://doi.org/10.1182/blood.V130.Suppl_1.4475.4475

Published: 2017

Journal Articles

Perforin Is Dispensable for Anti-CD19 CAR-T Cell Cytotoxicity but Contributes to CAR-T Cell Contraction and Regulates Host Inflammatory Response

Kazusa Ishii, MDMPH, Christopher Daniel Chien, PhD, Rebecca Erwin-Cohen, PhD, Howard A Young, PhD, Terry J. Fry, MD

Blood (2017) 130 (Supplement 1): 1918.

https://doi.org/10.1182/blood.V130.Suppl_1.1918.1918

Published: 2017

Journal Articles

Effect of Chronic Endogenous Antigen Stimulation on CAR T Cell Persistence and Memory Formation

Yinmeng Yang, PhD, Mark Eric Kohler, MD, PhD, Terry J. Fry, MD

Blood (2017) 130 (Supplement 1): 166.

https://doi.org/10.1182/blood.V130.Suppl_1.166.166

Published: 2017

Journal Articles

Beyond Cytokine Storm: Optimizing Treatment Strategies to Target the Complex Interplay between CAR Mediated Inflammatory Response, Disseminated Intravascular Coagulation and Macrophage Activation Syndrome

Nirali N Shah, MD, Haneen Shalabi, DO, Bonnie Yates, RN, Eli Kane, Alina Dulau-Florea, MD, Anne Cullinane, BS, Cynthia Delbrook, RN, Michael Ombrello, MD, Amanda Ombrello, MD, Jay Nelson Lozier, MD PhD, Terry J. Fry, MD

Blood (2017) 130 (Supplement 1): 1277.

https://doi.org/10.1182/blood.V130.Suppl_1.1277.1277

Published: 2017

Journal Articles

Direct Comparison of Anti-CD33 and Anti-CD123 Chimeric Antigen Receptor T Cells with CD28 or 41BB Co-Stimulatory Domains for Treatment of Acute Myeloid Leukemia

Samiksha Tarun, MSc, Haiying Qin, MS, Lila Yang, BS, Christopher Daniel Chien, PhD, Mark Eric Kohler, MD PhD, Terry J. Fry, MD

Blood (2017) 130 (Supplement 1): 1370.

https://doi.org/10.1182/blood.V130.Suppl_1.1370.1370

Published: 2017

Journal Articles

Chimeric Antigen Receptor Induced Cytopenia Differs from Chemotherapy Induced Myelosuppression

Haneen Shalabi, DO, Nirali N Shah, MD, Terry J. Fry, MD, Bonnie Yates, RN, Cynthia Delbrook, RN

Blood (2017) 130 (Supplement 1): 5048.

https://doi.org/10.1182/blood.V130.Suppl_1.5048.5048

Published: 2017

Journal Articles

Evaluating on-Target Toxicity of Hematopoietic-Targeting Cars Demonstrates Target-Nonspecific Suppression of Marrow Progenitors

Christopher Tor Sauter, BA, Christopher Daniel Chien, PhD, Feng Shen, MD PhD, Sarah K Tasian, MD, Terry J Fry, MD

Blood (2016) 128 (22): 3357.

https://doi.org/10.1182/blood.V128.22.3357.3357

Published: 2016

Journal Articles

Preclinical Development of FLT3-Redirected Chimeric Antigen Receptor T Cell Immunotherapy for Acute Myeloid Leukemia

Christopher Daniel Chien, PhD, Christopher Tor Sauter, BA, Kazusa Ishii, MD MPH, Sang Minh Nguyen, BS, Feng Shen, MD PhD, Sarah K Tasian, MD, Weizao Chen, PhD, Dimiter S Dimitrov, PhD, Terry J Fry, MD

Blood (2016) 128 (22): 1072.

https://doi.org/10.1182/blood.V128.22.1072.1072

Published: 2016

NARROW

Enhancing the Antigen-Sensitivity of the CD22 CAR through Modulation of the Affinity and Linker-Length of the Single-Chain Fragment Variable

Phase I Trial Using CD19/CD22 Bispecific CAR T Cells in Pediatric and Adult Acute Lymphoblastic Leukemia (ALL)

Infectious Complications Associated with CAR T-Cell Therapy

Low CD19 Antigen Density Diminishes Efficacy of CD19 CAR T Cells and Can be Overcome By Rational Redesign of CAR Signaling Domains

Phase I Experience with a Bi-Specific CAR Targeting CD19 and CD22 in Adults with B-Cell Malignancies

Phase 1 Study of CD19/CD22 Bispecific Chimeric Antigen Receptor (CAR) Therapy in Children and Young Adults with B Cell Acute Lymphoblastic Leukemia (ALL)

Sequential CD22 Targeting Impacts CD22 CAR-T Cell Response

CD4/CD8 T-Cell Selection Enhances CD22 CAR-T Cell Transduction and in-Vivo CAR-T Expansion: Updated Results on Phase I Anti-CD22 CAR Dose Expansion Cohort

Novel CD19/CD22 Bicistronic Chimeric Antigen Receptors Outperform Single or Bivalent Cars in Eradicating CD19 + CD22 + , CD19 - , and CD22 - Pre-B Leukemia

Intensification of Lymphodepletion Optimizes CAR Re-Treatment Efficacy

Modulation of CD22 Antigen Density Improves Efficacy of CD22 Chimeric Antigen Receptor (CAR) T Cells Against CD22 lo B-Lineage Leukemia and Lymphoma

A Direct Comparison of the In Vivo Efficacy and in Vitro Signaling of Chimeric Antigen Receptors and Endogenous T Cell Receptors

The Post-Thaw Recovery of Cryopreserved Chimeric Antigen Receptor (CAR) T-Cells during Manufacture Is Better Than That of Cryopreserved Peripheral Blood CD3+ Cells

Perforin Is Dispensable for Anti-CD19 CAR-T Cell Cytotoxicity but Contributes to CAR-T Cell Contraction and Regulates Host Inflammatory Response

Effect of Chronic Endogenous Antigen Stimulation on CAR T Cell Persistence and Memory Formation

Beyond Cytokine Storm: Optimizing Treatment Strategies to Target the Complex Interplay between CAR Mediated Inflammatory Response, Disseminated Intravascular Coagulation and Macrophage Activation Syndrome

Direct Comparison of Anti-CD33 and Anti-CD123 Chimeric Antigen Receptor T Cells with CD28 or 41BB Co-Stimulatory Domains for Treatment of Acute Myeloid Leukemia

Chimeric Antigen Receptor Induced Cytopenia Differs from Chemotherapy Induced Myelosuppression

Evaluating on-Target Toxicity of Hematopoietic-Targeting Cars Demonstrates Target-Nonspecific Suppression of Marrow Progenitors

Preclinical Development of FLT3-Redirected Chimeric Antigen Receptor T Cell Immunotherapy for Acute Myeloid Leukemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only